Notably, the Physical Activity Working Group of European Association for the Study of Obesity have recently highlighted that resistance training, rather aerobic exercise, attenuates lean body mass loss during weight-loss diets in adults with overweight or obesity ( Clinical studies using DEXA show that GLP-1based weight loss is accompanied by some loss of lean mass, but fat loss predominates
On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
Low back pain
The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
Even more, the regulatory story adds a cautionary note
